品牌战略推动中医药走向越南

中越两国的中医药交流源远流长,中越社会经济发展的差异性和文化的相似性,造就了我国中医药在越南市场上的巨大商机。我国中医药产业必须把握机遇,加强品牌建设,寻找合法途径,重点开拓越南中医药市场。     

以培养实践能力为主线的临床医学教学模式的研究与实践

为体现＂实用型＂人才培养的办学宗旨,必须加强临床实践能力的培养及重视临床基本技能的训练。通过文献法、论证法、问卷调查、测评、统计分析等研究方法来探索临床医学新的教学模式,形成以培养实践能力为主线的临床医学新的教学模式,同时优化了课程结构和教学内容。该教学模式的设计,符合认识规律,对提高学生知识技能很有帮助。     

基于新冠肺炎疫情防控的中药材发展研究

［目的］以中国新冠肺炎疫情阻击战为案例,通过成效、原因、问题的分析,研究提出对策措施,推动中医药高质量发展。［方法］运用文献研究法,梳理研究了有关中医药古籍、中药材栽培、新冠肺炎疫情防控与治疗等文献与数据,以问题为导向,提出了中医药事业发展的方向和路径。［结果］中医药在重大突发疫情防控中起到了非常重要的作用,中医药既有支撑抗击疫情取得胜利的深厚文化基础,又面临诸多问题和挑战,只要增强中医药的文化自信,采取综合措施,中医药就能够得到高质量发展。［结论］中医药成为该次抗疫的一大特色和亮点,在充分肯定中医药为抗疫斗争作出巨大贡献的同时,应客观正视中医药在认识、产业、质量等方面存在的突出问题,提出了大力弘扬中医药文化、加强政策引领、加强中医药科技创新、加强中医药国际合作等措施,特别是根据我国不同地域特点,提出了加强中药材基地规划建设的建议,以此推动中医药高质量发展。     

甘肃省中药材产业发展现状及对策研究

与全国其他地区相比,甘肃省在中药材资源、栽培面积及产量方面具有优势。省内相关地区已将中药材作为当地重要支柱产业,组织大规模的开发生产。该文从甘肃中药材产业的现状入手,在分析甘肃省中药材产业发展问题的基础上,提出了甘肃省发展中药材产业的对策建议,为甘肃的优势产业发展提出理论依据。     

大力发展中药材产业 积极推进中药材产业化

定西依托中药材的种植优势,把中药材作为当地重要支柱产业进行大规模地开发生产。通过调查研究,该文阐述了定西中药材种植概况、取得的成就和存在的主要问题,提出了如何积极推进中药材产业化的对策建议。     

中药材产业链特征及发展对策研究

该文对中药材产业的现状、作用进行了介绍,给出了中药材产业链的运行结构,分析了中药材产业链的特征及其对中药材原料的影响。在此基础上结合中药产业所处的经济环境,探讨了中药材产业应走循环经济之路及提高中药材品质和质量等4项对策。     

中药材种植对乡村振兴的影响

为了探讨我国中药材种植与乡村振兴的作用关系,基于2012—2021年30个省份（因数据缺失,未包括西藏地区和港澳台地区）的面板数据,利用广义GMM模型和面板门限模型对中药材种植面积与乡村振兴的关系进行实证研究,并对乡村振兴情况进行空间相关性分析。结果表明,无论采用何种方法,中药种植面积的系数估计值大多数为正,且在1%的显著性水平下显著;在乡村振兴程度介于-1.868和-1.457之间时,系数显著为正;全局Moran’s I均通过1%的显著性检验。由此得出结论,中药材种植可以促进我国乡村振兴进程;中药材种植只有在适当的经济发展水平下才能发挥其促进作用;要根据不同地区的实际情况制定相应的中药材种植策略和政策,助推乡村振兴。     

论药品广告机会主义

机会主义是指利用现行制度下一切可能的机会，甚至不惜损害他人或公共利益以谋求自身利益的最大化。当前，我国药品广告行业的相关制度还未完善，药品广告市场秩序较为混乱，机会主义乘机兴风作浪，大量违法药品广告肆无忌惮的粉墨登场，严重影响了人民群众的身体健康和生命安全。     

强的松辅以中成药治疗肾病综合征的疗效观察

为探寻难治性原发性肾病综合征(PNS)较为有效的治疗方案,对18例难治性PNS患者采用连续三个月足量强的松辅以中成药及部分患者加用环磷酰胺治疗。随访5~9年,临床观察完全缓解16例,占88.9%,15例未复发,复发1例,复发率为6.2%;无效2例,占11.1%。三个月足量强的松辅以中成药及部分患者加用环磷酰胺治疗难治性PNS疗效满意。     

Time-driven activity-based cost analysis for outpatient anticoagulation therapy: direct costs in a primary care setting with optimal performance

Objectives: To determine how overall cost of anticoagulation therapy for warfarin compares with that of Novel Oral Anticoagulants (NOACs). Also, to demonstrate a scientific, comprehensive, and an analytical approach to estimate direct costs involved in monitoring and management of anticoagulation therapy for outpatients in an academic primary care clinic setting, post-initiation of therapy.

Methods: A population-based cross-sectional study was conducted in conjunction with observations of patient care processes between August 2014 and January 2015. The study was conducted in an academic primary care outpatient setting at Mayo Clinic’s warfarin anticoagulation clinic, Rochester, MN. The anticoagulation clinic serves patients 18?years of age or older in Warfarin therapy management, for any indication, after referral from the patient’s primary care provider. The study included anticoagulation clinic enrollment data on a population of 5,526 patients. Time-Driven Activity-Based Costing (TDABC) technique was applied. Detailed process flow maps which showed process steps for all the anticoagulation program components and care continuum phases were created. Staff roles associated with each of the process steps were identified and displayed on the maps. Process times and costs were captured and analyzed. The main outcome was direct cost of monitoring and management of anticoagulation therapy, post-initiation of therapy.

Results: The cost of warfarin management for patients who display unstable International Normalized Ratio (INR) is more than three times those who display stable INR over time. (Comparator to distinguish stability: Frequency of point-of-care visits needed by patients.) For complex anticoagulation patients, total cost of medication and monitoring for warfarin anticoagulation therapy is similar to that for NOACs.

Conclusion: Despite warfarin being significantly less expensive to purchase than NOACs, overall warfarin management incurs higher costs due to laboratory monitoring and provider time than NOACs. NOAC treatment, therefore, may not be more expensive than warfarin therapy management for complex anticoagulation patients.